Triptorelin ( DrugBank: Triptorelin )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 49 | 全身性エリテマトーデス | 1 |
| 76 | 下垂体性ゴナドトロピン分泌亢進症 | 6 |
49. 全身性エリテマトーデス
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00124514 (ClinicalTrials.gov) | June 2003 | 26/7/2005 | Triptorelin for Ovary Protection in Childhood Onset Lupus | Systemic Lupus Erythematosus | Drug: Triptorelin pamoate | Children's Hospital Medical Center, Cincinnati | Watson Pharmaceuticals | Completed | 9 Years | 21 Years | Female | 30 | Phase 2 | United States;Brazil |
76. 下垂体性ゴナドトロピン分泌亢進症
臨床試験数 : 28 / 薬物数 : 46 - (DrugBank : 14) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 19
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05029622 (ClinicalTrials.gov) | August 10, 2021 | 9/8/2021 | A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty. | A Phase III, Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Chinese Paediatric Participants With Central Precocious Puberty. | Central Precocious Puberty | Drug: Triptorelin Pamoate | Ipsen | NULL | Recruiting | N/A | 10 Years | All | 66 | Phase 3 | China |
| 2 | NCT04736602 (ClinicalTrials.gov) | March 27, 2021 | 29/1/2021 | Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty. | An Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of Triptorelin 3-month Formulation in Chinese Children With Central Precocious Puberty | Central Precocious Puberty | Drug: Triptorelin pamoate 15mg | Ipsen | NULL | Active, not recruiting | N/A | 10 Years | All | 32 | Phase 3 | China |
| 3 | NCT01467882 (ClinicalTrials.gov) | April 2012 | 7/11/2011 | Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty | An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty | Central Precocious Puberty | Drug: Triptorelin | Debiopharm International SA | NULL | Completed | 2 Years | 9 Years | All | 44 | Phase 3 | United States;Chile;Mexico |
| 4 | NCT01278290 (ClinicalTrials.gov) | December 2009 | 14/1/2011 | Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls | Triptorelin Acetate Utilization for the Early Diagnosis of Central Precocious Puberty (CPP) in Girls. | Central Precocious Puberty;Sexual Precocity | Diagnostic Test: Triptorelin acetate and Gonadorelin acetate;Diagnostic Test: Gonadorelin acetate and Triptorelin acetate | Hospital de Niños R. Gutierrez de Buenos Aires | NULL | Completed | 3 Years | 8 Years | Female | 46 | Phase 3 | Argentina |
| 5 | NCT00438217 (ClinicalTrials.gov) | May 2006 | 21/2/2007 | Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children | Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children | Central Precocious Puberty | Drug: Triptorelin (GnRH agonists);Drug: Leuprolide (GnRH agonists) | University of Pisa | NULL | Recruiting | 1 Year | 18 Years | Both | 100 | Phase 4 | Italy |
| 6 | EUCTR2015-001607-30-Outside-EU/EEA (EUCTR) | 24/04/2015 | Triptorelin 6-month formulation for children who mature too early because of a brain hormone | An open-label, non-comparative, multicenter study on the efficacy, safety, and pharmacokinetics of triptorelin pamoate (embonate) 22.5 mg 6-month formulation in patients suffering from central (gonadotropin-dependent) precocious puberty - Triptorelin 6-month Formulation in Patients With Central Precocious Puberty | Central Precocious Puberty MedDRA version: 18.0;Level: PT;Classification code 10058084;Term: Precocious puberty;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Biological Phenomena [G16] | INN or Proposed INN: TRIPTORELIN Other descriptive name: Triptorelin embonate, Triptorelin pamoate | Debiopharm International, S.A. | NULL | NA | Female: yes Male: yes | 44 | United States;Chile;Mexico |